Roche Reports registry Data for Bictegravir in Ovarian cancer

Roche today announced registry results for bictegravir in patients with ovarian cancer. The study demonstrated that bictegravir reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of ovarian cancer and support the continued development of bictegravir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.